We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+12.87%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$431M
AUM Growth
+$70.9M
Cap. Flow
+$79.1M
Cap. Flow %
18.34%
Top 10 Hldgs %
23.13%
Holding
178
New
54
Increased
29
Reduced
23
Closed
43

Top Buys

Rank Stock Value
1
XTNT icon
Xtant Medical Holdings
XTNT
+$14.7M
2
PALI icon
Palisade Bio
PALI
+$11M
3
POL.WS
Polished.com Inc. Warrants to Purchase Common Stock
POL.WS
+$10.1M
4
ECOR icon
electroCore
ECOR
+$8.6M
5
KLR
Kaleyra, Inc.
KLR
+$8.24M

Top Sells

Rank Stock Value
1
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
+$8.32M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.67M
3
STRO icon
Sutro Biopharma
STRO
+$5.16M
4
MBTCU
Nocturne Acquisition Corporation Unit
MBTCU
+$5M
5
IMNN icon
Imunon
IMNN
+$4.83M

Sector Composition

Rank Sector Weight
1 Healthcare 84.75%
2 Financials 3.74%
3 Technology 1.96%
4 Consumer Discretionary 0.54%
5 Industrials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MORF
76
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$2.33M 0.54%
40,541
-6,000
-13% -$330K
FULC icon
77
Fulcrum Therapeutics
FULC
$288M
$2.24M 0.52%
+213,533
New +$2.16M
FATBW
78
DELISTED
FAT Brands Inc. Warrant
FATBW
$2.23M 0.52%
233,697
-66,303
-22% -$390K
GRTX
79
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$2.16M 0.5%
+219,900
New +$1.79M
TVRD
80
Tvardi Therapeutics
TVRD
$18.8M
$2.14M 0.5%
+4,167
New +$2.64M
RYTM icon
81
Rhythm Pharmaceuticals
RYTM
$7.59B
$2.05M 0.48%
104,840
-118,160
-53% -$2.45M
TARS icon
82
Tarsus Pharmaceuticals
TARS
$2.67B
$2.04M 0.47%
+70,573
New +$2.2M
LAAAU
83
DELISTED
Lakeshore Acquisition I Corp. Unit
LAAAU
$2.04M 0.47%
+200,000
New +$2.01M
GIWWU
84
DELISTED
GigInternational1, Inc. Units
GIWWU
$2.01M 0.47%
+200,000
New +$2M
PRDS
85
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$2M 0.46%
200,000
– –
JYAC
86
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$1.99M 0.46%
200,000
– –
HCAQ
87
DELISTED
HealthCor Catalio Acquisition Corp. Class A Ordinary Shares
HCAQ
$1.97M 0.46%
200,000
– –
VANI icon
88
Vivani Medical
VANI
$119M
$1.85M 0.43%
+124,622
New +$2.41M
IMCC
89
IM Cannabis
IMCC
$1.13M
$1.71M 0.4%
+5,364
New +$1.77M
EIGR
90
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.68M 0.39%
6,583
– –
CVRX icon
91
CVRx
CVRX
$148M
$1.68M 0.39%
+60,000
New +$1.68M
CYTK icon
92
Cytokinetics
CYTK
$10.7B
$1.67M 0.39%
84,262
-19,000
-18% -$446K
KRBP
93
DELISTED
Kiromic BioPharma, Inc. Common Stock
KRBP
$1.6M 0.37%
+11,116
New +$2.79M
PCTTW
94
PureCycle Technologies Inc Warrant
PCTTW
$10.9M
$1.6M 0.37%
+130,875
New +$1.41M
ALP
95
Alpha Compute
ALP
$4.33M
$1.57M 0.36%
+3,750
New +$2.22M
ACET icon
96
Adicet Bio
ACET
$85.6M
$1.46M 0.34%
8,893
– –
KA
97
DELISTED
Kineta, Inc. Common Stock
KA
$1.44M 0.33%
17,670
+2,142
+14% +$231K
VINC
98
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$1.4M 0.32%
+5,381
New +$1.64M
ELOX
99
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$1.33M 0.31%
+16,753
New +$1.4M
BURU
100
DELISTED
NUBURU INC
BURU
$1.28M 0.3%
643
– –
2 3
4
5 6

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
LSA
Liberty Street Advisors New York $41.4M AUM 34.47% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return

Altium Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Altium Capital Management held 178 positions worth $431M, up 20% from $360M the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Altium Capital Management deployed $79.1M of net new capital in Q2 2021, opening 54 new positions and adding to 29 existing holdings. Its largest new stake was Xtant Medical Holdings: 8,292,602 shares worth $13.5M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 83% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Verastem, an estimated $2.98M trimmed.

  • Altium Capital Management's largest Q2 2021 buy was Xtant Medical Holdings: 8,292,602 shares worth $13.5M.
  • Altium Capital Management added most to CTI BioPharma Corp. (DE) Common Stock in Q2 2021, an estimated $7.41M increase.
  • Altium Capital Management's biggest Q2 2021 reduction was Verastem, cutting an estimated $2.98M.
  • Altium Capital Management fully exited Biora Therapeutics, Inc. Common Stock in Q2 2021, selling an estimated $8.32M.
  • Altium Capital Management's ten largest holdings make up 23% of its $431M portfolio in Q2 2021.
  • Altium Capital Management opened 54 new positions and closed 43 in Q2 2021.
  • Altium Capital Management's portfolio value rose 20% quarter-over-quarter to $431M.

Based on Altium Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.